Data gathered: May 30
AI Stock Analysis - Genmab A/S (GMAB)
Analysis generated May 11, 2025. Powered by Chat GPT.
Genmab A/S is a Copenhagen-based biotechnology company specializing in the development of antibody therapies for the treatment of cancer. The company has a diversified portfolio of active clinical and preclinical programs, with a focus on developing novel therapeutic products. Genmab has established itself as a key player in the biotech industry with several marketed products and collaborations with other prominent pharmaceutical companies.
Stock Alerts - Genmab A/S (GMAB)
 |
Genmab A/S | May 6 Employee Rating is down by 2.3% over the last month. |
|
Genmab A/S | May 6 Business Outlook among employees is down by 3.7% over the last month. |
|
Genmab A/S | April 22 Business Outlook among employees is up by 3.8% over the last month. |
|
Genmab A/S | April 18 AI Score is up by 20.3% in the last couple of days. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Genmab A/S
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 79 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 62,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,015 | Sign up | Sign up | Sign up |
| Twitter Followers | 7,996 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| Youtube Subscribers | 412 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 78 | Sign up | Sign up | Sign up |
| Linkedin Employees | 2,586 | Sign up | Sign up | Sign up |
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
| Price | $20.79 |
| Target Price | Sign up |
| Volume | 146,860 |
| Market Cap | $13.1B |
| Year Range | $17.98 - $25.53 |
| Dividend Yield | 0% |
| PE Ratio | 12.46 |
| Analyst Rating | 43% buy |
| Industry | Biotechnology |
In the news
 |
Genmab A/S: Transitioning From Royalty Model To Commercial-Stage OncologyMay 18 - SeekingAlpha |
 |
Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?April 30 - Yahoo |
|
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare ConferenceMay 26 - Yahoo |
|
Transactions in Connection with Share Buy-back ProgramMay 25 - Yahoo |
Capital Increase in Genmab as a Result of Employee Warrant ExerciseMay 20 - GlobeNewswire |
|
|
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)May 1 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 715M | 42M | 673M | 195M | 265M | 0.305 |
| Q4 '24 | 6.44B | 337M | 6.1B | 3.85B | 2.36B | 0.835 |
| Q3 '24 | 5.54B | 273M | 5.27B | 1.27B | 1.85B | 0.290 |
| Q2 '24 | 5.4B | 190M | 5.21B | 1.41B | 2.15B | 0.310 |
| Q1 '24 | 4.14B | 185M | 3.96B | 1.33B | 861M | 0.290 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Josh Gottheimer |
Feb 11, 25 | Buy | $1K - $15K |
| Josh Gottheimer |
Jan 15, 25 | Sell | $1K - $15K |
| Josh Gottheimer |
Aug 15, 24 | Buy | $1K - $15K |
Read more about Genmab A/S (GMAB) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Genmab A/S?
The Market Cap of Genmab A/S is $13.1B.
What is Genmab A/S's PE Ratio?
As of today, Genmab A/S's PE (Price to Earnings) ratio is 12.46.
What is the current stock price of Genmab A/S?
Currently, the price of one share of Genmab A/S stock is $20.79.
How can I analyze the GMAB stock price chart for investment decisions?
The GMAB stock price chart above provides a comprehensive visual representation of Genmab A/S's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Genmab A/S shares. Our platform offers an up-to-date GMAB stock price chart, along with technical data analysis and alternative data insights.
Does GMAB offer dividends to its shareholders?
As of our latest update, Genmab A/S (GMAB) does not offer dividends to its shareholders. Investors interested in Genmab A/S should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Genmab A/S?
Some of the similar stocks of Genmab A/S are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.